LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI

14 May 2026 Isomorphic Labs said the funding round, led by venture firm Thrive Capital, would be used to further its drug design engine and support hiring targets.

Careers

Blank Rome adds to growing team with patent agent from MBHB

14 May 2026 The biotechnology and life sciences specialist joins from McDonnell Boehnen Hulbert & Berghoff, marking the fifth senior IP hire at the firm this year.

Americas

BMS signs $15.2bn deal with China’s top pharma company

14 May 2026 The agreement is the latest in a string of major deals between Hengrui and multinational drugmakers, and will see the parties jointly develop assets while licensing others.

More features

UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI

Blank Rome adds to growing team with patent agent from MBHB

BMS signs $15.2bn deal with China’s top pharma company

Medtech company sues over seven patents for incontinence products

10x Genomics settles suit with rival and targets DNA sequencing startup

Trade secrets, AI and the new scrutiny of big damages awards

WATCH: Interview with Mythili Markowski, director at Regeneron

IP in the deal room: The risks that bite before, during and after closing

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

More on this story

Editor's picks

Editor's picks

More features